The Global Antibiotic Research & Development Partnership (GARDP) is a non-profit R&D body launched jointly by the WHO and DNDi in partnership with Entasis Therapeutics to develop a novel first-in-class antibiotic zoliflodacin to address drug-resistant gonorrhoea.
